Pirfenidone inhibits myofibroblast differentiation and lung fibrosis development during insufficient mitophagy
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Pirfenidone (PFD) is an anti-fibrotic agent used to treat idiopathic pulmonary fibrosis (IPF), but its precise mechanism of action remains elusive. Accumulation of profibrotic myofibroblasts is a crucial process for fibrotic remodeling in IPF. Recent findings show participation of autophagy/mitophagy, part of the lysosomal degradation machinery, in IPF pathogenesis. Mitophagy has been implicated in myofibroblast differentiation through regulating mitochondrial reactive oxygen species (ROS)-mediated platelet-derived growth factor receptor (PDGFR) activation. In this study, the effect of PFD on autophagy/mitophagy activation in lung fibroblasts (LF) was evaluated, specifically the anti-fibrotic property of PFD for modulation of myofibroblast differentiation during insufficient mitophagy. METHODS: Transforming growth factor-β (TGF-β)-induced or ATG5, ATG7, and PARK2 knockdown-mediated myofibroblast differentiation in LF were used for in vitro models. The anti-fibrotic role of PFD was examined in a bleomycin (BLM)-induced lung fibrosis model using PARK2 knockout (KO) mice. RESULTS: We found that PFD induced autophagy/mitophagy activation via enhanced PARK2 expression, which was partly involved in the inhibition of myofibroblast differentiation in the presence of TGF-β. PFD inhibited the myofibroblast differentiation induced by PARK2 knockdown by reducing mitochondrial ROS and PDGFR-PI3K-Akt activation. BLM-treated PARK2 KO mice demonstrated augmentation of lung fibrosis and oxidative modifications compared to those of BLM-treated wild type mice, which were efficiently attenuated by PFD. CONCLUSIONS: These results suggest that PFD induces PARK2-mediated mitophagy and also inhibits lung fibrosis development in the setting of insufficient mitophagy, which may at least partly explain the anti-fibrotic mechanisms of PFD for IPF treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402582 · Cited by 3,975
Autophagy and the Integrated Stress Response
Kroemer, G., Mariño, G., & Levine, B. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.09.023 · Cited by 3,506 · cited 1×
“In addition, proper turnover of damaged organelles by selective autophagy is considered to be cytoprotective during the integrated stress response [16, 17].”
BackgroundKing, T. E., Pardo, A., & Selman, M. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60052-4 · Cited by 2,194
PINK1 deficiency impairs mitochondrial homeostasis and promotes lung fibrosis
Bueno, M., Lai, Y.-C., Romero, Y., Brands, J., St. Croix, C. M., Kamga, C., Corey, C., Herazo-Maya, J. D., Sembrat, J., Lee, J. S., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci74942 · Cited by 627 · cited 3×
“Accordingly, we speculate that PFD-iron complex formation can be an important molecular mechanism for lung fibrosis attenuation through reducing both free iron and mitochondrial ROS in IPF lungs where there is increased iron deposition and insufficient mitophagy [27, 30].”
BackgroundResultConte, E., Gili, E., Fagone, E., Fruciano, M., Iemmolo, M., & Vancheri, C. (2014) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2014.02.014 · Cited by 368 · cited 1×
“Anti-fibrotic mechanisms for PFD have been postulated to be mainly attributed to attenuating protein levels and signaling pathways of pro-fibrotic growth factors, including transforming growth factor (TGF)-β, platelet-derived growth factor (PDGF), and basicfibroblast growth factor (bFGF) [7, 10, 11].”
BackgroundNovel mechanisms for the antifibrotic action of nintedanib
Rangarajan, S., Kurundkar, A., Kurundkar, D., Bernard, K., Sanders, Y. Y., Ding, Q., Antony, V. B., Zhang, J., Zmijewski, J., & Thannickal, V. J. (2016) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2014-0445oc · Cited by 238 · cited 1×
“canonical autophagy, which was not involved in the anti-fibrotic mechanisms of nintedanib [21].”
BackgroundInvolvement of PARK2-Mediated Mitophagy in Idiopathic Pulmonary Fibrosis Pathogenesis
Kobayashi, K., Araya, J., Minagawa, S., Hara, H., Saito, N., Kadota, T., Sato, N., Yoshida, M., Tsubouchi, K., Kurita, Y., et al. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1600265 · Cited by 145 · cited 8×
“Recent papers, including our findings, propose a role for the accumulation of mitochondrial ROS in IPF pathogenesis due to impaired mitophagy [20, 27].”
BackgroundMethodSelf-citation
Cited by
Complex interplay between autophagy and oxidative stress in the development of pulmonary disease
Ornatowski, W., Lu, Q., Yegambaram, M., Garcia, A. E., Zemskov, E. A., Maltepe, E., Fineman, J. R., Wang, T., & Black, S. M. (2020) · Redox Biology · doi:10.1016/j.redox.2020.101679 · Cited by 467
Myofibroblasts and Fibrosis: Mitochondrial and Metabolic Control of Cellular Differentiation
Gibb, A. A., Lazaropoulos, M. P., & Elrod, J. W. (2020) · Circulation Research · doi:10.1161/circresaha.120.316958 · Cited by 434
Emerging cellular and molecular determinants of idiopathic pulmonary fibrosis
Phan, T. H. G., Paliogiannis, P., Nasrallah, G. K., Giordo, R., Eid, A. H., Fois, A. G., Zinellu, A., Mangoni, A. A., & Pintus, G. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03693-7 · Cited by 351
Pirfenidone: Molecular mechanisms and potential clinical applications in lung disease
Ruwanpura, S. M., Thomas, B. J., & Bardin, P. G. (2020) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2019-0328tr · Cited by 317
The Role of Macrophages in the Development of Acute and Chronic Inflammatory Lung Diseases
Lee, J.-W., Chun, W., Lee, H. J., Min, J.-H., Kim, S.-M., Seo, J.-Y., Ahn, K.-S., & Oh, S.-R. (2021) · Cells · doi:10.3390/cells10040897 · Cited by 291
Metadata
- Authors
- Kurita, Y., Araya, J., Minagawa, S., Hara, H., Ichikawa, A., Saito, N., Kadota, T., Tsubouchi, K., Sato, N., Yoshida, M., Kobayashi, K., Ito, S., Fujita, Y., Utsumi, H., Yanagisawa, H., Hashimoto, M., Wakui, H., Yoshii, Y., Ishikawa, T., Numata, T., Kaneko, Y., Asano, H., Yamashita, M., Odaka, M., Morikawa, T., Nakayama, K., & Kuwano, K.
- Venue
- Respiratory Research
- Published
- 2017-06-02
- Volume
- 18
- Issue
- 1
- Pages
- 114-114
- ISSN
- 1465-9921 (ISSN-L)
- 1465-993X
- OpenAlex
- W2621087035
- Cited by
- 98
- References
- 8
- FWCI
- 7.90
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pirfenidone inhibits myofibroblast differentiation and lung fibrosis development during insufficient mitophagy. https://app.cochat.ai/papers/10.1186/s12931-017-0600-3
- The paper
- Kurita, Y., Araya, J., Minagawa, S., Hara, H., Ichikawa, A., Saito, N., Kadota, T., Tsubouchi, K., Sato, N., Yoshida, M., Kobayashi, K., Ito, S., Fujita, Y., Utsumi, H., Yanagisawa, H., Hashimoto, M., Wakui, H., Yoshii, Y., Ishikawa, T., . . . Kuwano, K. (2017). Pirfenidone inhibits myofibroblast differentiation and lung fibrosis development during insufficient mitophagy. Respiratory Research. https://doi.org/10.1186/s12931-017-0600-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.